The complaint alleges that Lantheus and its executives misled investors about the growth and pricing strength of Pylarify, its key prostate cancer imaging product, during the class period. The company repeatedly assured investors that Pylarify’s market leadership and premium pricing would support revenue growth, while concealing that price hikes and competitive pressures were eroding its market position. When quarterly results in May and August 2025 revealed sharp sales declines, reduced guidance, and intensifying competition, Lantheus’ stock dropped over 23% and 28% on those respective dates. The lawsuit claims that investors purchased shares at artificially inflated prices due to these misrepresentations.
Contact our attorneys for a no-cost case evaluation.